GH Research PLC $GHRS Shares Sold by BVF Inc. IL

Key Points

• BVF Inc. IL reduced its stake in GH Research PLC by 15.1%, now holding 8,827,712 shares, which constitutes about 4.0% of its investment portfolio.
• GH Research reported an EPS of ($0.15) for the last quarter, surpassing analyst estimates of ($0.22).
• Analysts maintain an average rating of "Moderate Buy" for GH Research, with a consensus price target of $32.00.

BVF Inc. IL lessened its stake in shares of GH Research PLC (NASDAQ:GHRS - Free Report) by 15.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,827,712 shares of the company's stock after selling 1,572,446 shares during the quarter. GH Research comprises about 4.0% of BVF Inc. IL's investment portfolio, making the stock its 7th biggest position. BVF Inc. IL owned about 16.97% of GH Research worth $97,370,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the stock. BNP Paribas Financial Markets acquired a new stake in GH Research during the 4th quarter valued at $44,000. Northern Trust Corp boosted its holdings in shares of GH Research by 26.8% during the fourth quarter. Northern Trust Corp now owns 40,834 shares of the company's stock worth $286,000 after purchasing an additional 8,641 shares during the last quarter. Palumbo Wealth Management LLC acquired a new stake in shares of GH Research during the first quarter worth $142,000. XTX Topco Ltd acquired a new stake in shares of GH Research during the first quarter worth $169,000. Finally, Two Sigma Investments LP acquired a new stake in shares of GH Research during the fourth quarter worth $117,000. Institutional investors and hedge funds own 56.90% of the company's stock.

Wall Street Analyst Weigh In

GHRS has been the topic of several analyst reports. Wall Street Zen upgraded GH Research from a "sell" rating to a "hold" rating in a report on Saturday, July 5th. JMP Securities restated a "market outperform" rating and set a $39.00 price objective on shares of GH Research in a report on Tuesday, June 24th. Cantor Fitzgerald started coverage on GH Research in a report on Wednesday, June 4th. They set an "overweight" rating and a $25.00 price objective on the stock. Finally, Zacks Research cut GH Research from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 13th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $32.00.

GH Research Trading Down 2.8%

NASDAQ:GHRS traded down $0.40 during mid-day trading on Monday, hitting $13.70. The company had a trading volume of 105,240 shares, compared to its average volume of 327,606. The business has a fifty day simple moving average of $14.18 and a 200-day simple moving average of $12.10. GH Research PLC has a 1 year low of $6.00 and a 1 year high of $20.50. The firm has a market capitalization of $712.52 million, a price-to-earnings ratio of -18.51 and a beta of 0.97.

GH Research (NASDAQ:GHRS - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.07. As a group, research analysts anticipate that GH Research PLC will post -0.8 earnings per share for the current year.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).